Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of "Buy" by Analysts

Key Points

• Analysts maintain a bullish view: Niagen Bioscience has an average “Buy” rating from five analysts, with an average 12-month price target of $10.33.
• Shares have declined recently: NAGE opened at $3.00, near its 12-month low of $2.87, versus a 12-month high of $10.19; the stock was trading below both its 50-day and 200-day moving averages.
• Quarterly results met expectations: The company reported $0.01 in adjusted earnings per share, matching consensus, while revenue of $29.78 million fell slightly short of the $29.95 million estimate. Institutional investors own 15.41% of the stock.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) has earned an average recommendation of "Buy" from the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $10.3333.

A number of research analysts recently weighed in on NAGE shares. HC Wainwright restated a "buy" rating on shares of Niagen Bioscience in a research note on Wednesday, July 1st. Roth Capital reiterated a "buy" rating on shares of Niagen Bioscience in a research note on Wednesday, August 5th. Freedom Capital raised Niagen Bioscience to a "strong-buy" rating in a report on Monday, July 6th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Niagen Bioscience in a research report on Friday, July 17th.

Niagen Bioscience Trading Down 2.9%

NASDAQ NAGE opened at $3.00 on Thursday. Niagen Bioscience has a 12 month low of $2.87 and a 12 month high of $10.19. The stock has a market cap of $238.92 million, a price-to-earnings ratio of 16.67 and a beta of 2.09. The company's 50 day moving average is $3.17 and its two-hundred day moving average is $3.76.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, hitting analysts' consensus estimates of $0.01. The business had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. Sell-side analysts forecast that Niagen Bioscience will post 0.13 EPS for the current year.

Institutional Trading of Niagen Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. SteelPeak Wealth LLC bought a new position in Niagen Bioscience in the 1st quarter worth approximately $14,875,000. Arrowstreet Capital Limited Partnership raised its position in shares of Niagen Bioscience by 47.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company's stock valued at $10,489,000 after buying an additional 761,685 shares during the last quarter. Tieton Capital Management LLC purchased a new position in shares of Niagen Bioscience in the second quarter worth $6,407,000. Renaissance Technologies LLC lifted its holdings in shares of Niagen Bioscience by 45.4% in the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company's stock worth $5,860,000 after buying an additional 414,725 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Niagen Bioscience by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,071,133 shares of the company's stock worth $4,723,000 after acquiring an additional 150,763 shares during the last quarter. Institutional investors own 15.41% of the company's stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a bioscience company focused on developing and commercializing products designed to support healthy aging and cellular energy metabolism. The company's research centers on nicotinamide riboside (NR), a form of vitamin B3 and precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in numerous cellular processes.

The company markets its proprietary NIAGEN branded NR ingredient to supplement manufacturers and sells consumer products under the Tru Niagen brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.